These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 15286714

  • 1. Parity-induced mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic mice.
    Henry MD, Triplett AA, Oh KB, Smith GH, Wagner KU.
    Oncogene; 2004 Sep 09; 23(41):6980-5. PubMed ID: 15286714
    [Abstract] [Full Text] [Related]

  • 2. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis.
    Rudolph-Owen LA, Chan R, Muller WJ, Matrisian LM.
    Cancer Res; 1998 Dec 01; 58(23):5500-6. PubMed ID: 9850086
    [Abstract] [Full Text] [Related]

  • 3. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.
    Zinser GM, Welsh J.
    Carcinogenesis; 2004 Dec 01; 25(12):2361-72. PubMed ID: 15333467
    [Abstract] [Full Text] [Related]

  • 4. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice.
    Zhou H, Chen WD, Qin X, Lee K, Liu L, Markowitz SD, Gerson SL.
    Oncogene; 2001 Sep 20; 20(42):6009-17. PubMed ID: 11593408
    [Abstract] [Full Text] [Related]

  • 5. Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-beta1 expression.
    Boulanger CA, Wagner KU, Smith GH.
    Oncogene; 2005 Jan 20; 24(4):552-60. PubMed ID: 15580303
    [Abstract] [Full Text] [Related]

  • 6. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
    Zelazny E, Li B, Anagnostopoulos AM, Coleman A, Perkins AS.
    Exp Mol Pathol; 2001 Jun 20; 70(3):183-93. PubMed ID: 11417997
    [Abstract] [Full Text] [Related]

  • 7. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability.
    McCormack SJ, Weaver Z, Deming S, Natarajan G, Torri J, Johnson MD, Liyanage M, Ried T, Dickson RB.
    Oncogene; 1998 May 28; 16(21):2755-66. PubMed ID: 9652742
    [Abstract] [Full Text] [Related]

  • 8. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S, Tinnirello A, Di Stefano P, Bisarò B, Ambrosino E, Castellano I, Sapino A, Arisio R, Cavallo F, Forni G, Glukhova M, Silengo L, Altruda F, Turco E, Tarone G, Defilippi P.
    Cancer Res; 2006 May 01; 66(9):4672-80. PubMed ID: 16651418
    [Abstract] [Full Text] [Related]

  • 9. Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis.
    Gallahan D, Jhappan C, Robinson G, Hennighausen L, Sharp R, Kordon E, Callahan R, Merlino G, Smith GH.
    Cancer Res; 1996 Apr 15; 56(8):1775-85. PubMed ID: 8620493
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
    Liu JC, Deng T, Lehal RS, Kim J, Zacksenhaus E.
    Cancer Res; 2007 Sep 15; 67(18):8671-81. PubMed ID: 17875707
    [Abstract] [Full Text] [Related]

  • 13. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis.
    Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC, Lindeman GJ, Visvader JE.
    Cancer Res; 2008 Oct 01; 68(19):7711-7. PubMed ID: 18829523
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia.
    Daphna-Iken D, Shankar DB, Lawshé A, Ornitz DM, Shackleford GM, MacArthur CA.
    Oncogene; 1998 Nov 26; 17(21):2711-7. PubMed ID: 9840935
    [Abstract] [Full Text] [Related]

  • 16. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice.
    Krane IM, Leder P.
    Oncogene; 1996 Apr 18; 12(8):1781-8. PubMed ID: 8622899
    [Abstract] [Full Text] [Related]

  • 17. Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression.
    Corsino P, Davis B, Law M, Chytil A, Forrester E, Nørgaard P, Teoh N, Law B.
    Cancer Res; 2007 Apr 01; 67(7):3135-44. PubMed ID: 17409420
    [Abstract] [Full Text] [Related]

  • 18. Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice.
    van Rossum AG, van Bragt MP, Schuuring-Scholtes E, van der Ploeg JC, van Krieken JH, Kluin PM, Schuuring E.
    BMC Cancer; 2006 Mar 14; 6():58. PubMed ID: 16536875
    [Abstract] [Full Text] [Related]

  • 19. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.
    Jacquemart IC, Springs AE, Chen WY.
    Int J Oncol; 2009 Feb 14; 34(2):517-28. PubMed ID: 19148488
    [Abstract] [Full Text] [Related]

  • 20. Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice.
    Elson A.
    Oncogene; 1999 Dec 09; 18(52):7535-42. PubMed ID: 10602512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.